Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Clinical Study Evaluating Luminate® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion

Creators: Kuppermann, Baruch D.; Boyer, David S.; Kaiser, Peter K.; Heier, Jeffrey S.; Campochiaro, Peter A.; Quiroz-Mercado, Hugo; Kornfield, Julia; Karageozian, Lisa; Genead, Mohamed A.; Karageozian, Hampar L.; Karageozian, Vicken H.

Abstract

Purpose : To investigate the safety and efficacy of Luminate (ALG-1001), a synthetic anti-angiogenic and vitreolytic oligopeptide, administered intravitreally in patients with focal vitreomacular adhesion (VMA) or vitreomacular traction (VMT).

Additional Information

These abstracts are licensed under a Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International License. Go to http://iovs.arvojournals.org/ to access the versions of record.

Attached Files

Published - Kuppermann_2016p1809.pdf

Files

Kuppermann_2016p1809.pdf

Files (676.5 kB)

Name	Size	Download all
Kuppermann_2016p1809.pdf md5:4cf980c1c820924b0021f094a9373259	676.5 kB	Preview Download

Additional details

	All versions	This version
Views	0	0
Downloads	0	0
Data volume	0 Bytes	0 Bytes